19th Annual Cancer Progress Conference
March 11-12, 2008
Note: The 2009 program will be posted soon
Moderators:
Jeremy P. Goldberg
Managing Director, Corporate Development
Endo Pharmaceuticals
Mark J. Simon
Industry Consultant
Williver Group, LLC
Keynote Presentation: Targeting the Ras Pathway
Frank
McCormick, Ph.D., FRS
Director
UCSF
Scott
W. Lowe, Ph.D.
Professor,
Cold Spring Harbor Laboratory
Deputy Director, Cold Spring Harbor Laboratory
Cancer Center
HHMI Investigator
Special Presentation:
Combinatorial Approaches in Molecular
Targeted Therapies –
Rationale for Multi-Targeting in Cancer
Scott E. Kern, M.D.
Professor of Oncology
The Sidney Kimmel Cancer Center at
Johns Hopkins
Panel
Discussion: Targeted
Therapies – Where Are We Now?
Moderator:
Richard
E.
Smith,
Ph.D.
Vice President & Senior Biotechnology Analyst
JP Morgan
Panelists: Bruce A. Chabner, M.D.
Clinical Director
Massachusetts General
David Heimbrook,
Ph.D.
Vice President, Research
Disease Biology Area Head, Discovery
Oncology
Roche
Carlos L.
Arteaga, M.D.
Professor of Medicine and Cancer Biology
Director, VICC Breast Cancer Program, Division of Oncology
Vanderbilt-Ingram
Panel Discussion: Biomarkers -
Are We There Yet?
Moderator:
Vice President, Franchise Integrator, Oncology
Merck
& Co.
Panelists: Samir Khleif, Ph.D.
Chief, Cancer Vaccine Section
National Cancer Institute
David R. Parkinson, M.D.
President & CEO
Nodality, Inc.
Nicholas Dracopoli, Ph.D.
Vice President, Biomarkers
Centocor Research & Development, Inc.
Donald
A.
Bergstrom, M.D.,
Ph.D.
Director, Experimental Medicine - Oncology
Merck & Co., Inc.
Mark J.
Ratain, M.D.
Chairman, Committee on Clinical Pharmacology
& Pharmacogenomics
Leon O. Jacobson, Professor of Medicine, Cancer Research Center
University of
Chicago
Colin
Hill
CEO
Gene Network Sciences
Moderator: Richard
Gaynor, M.D.
Vice President Cancer Research and Clinical Investigation
Eli Lilly & Company
Panelists: Ira Mellman, Ph.D.
Vice President, Oncology Research
Genentech
Ian
Taylor, Ph.D.
Director,
Translational Medicine, Oncology
Pfizer PGRD
Peter T. Ho, M.D., Ph.D.
Senior
Vice President, Oncology CEDD
GlaxoSmithKline Pharmaceuticals Corp.
Catherine
A.
Wheeler, M.D.
Executive Director, Oncology Clinical Development
Roche
Panel Discussion: Genes
Set The Stage for Metastasis – Targets for Therapeutic Intervention
Moderator:
Gregory
K.
Frykman, M.D.
Senior Vice President, Pharmaceuticals and Biotechnology
Stanford Washington Research Group
Panelists: Joan Massague, Ph.D.
Chairman, Cancer Biology and Genetics
Program, HHMI
Memorial-Sloan
Yibin Kang, Ph.D.
Assistant Professor of Molecular Biology
Princeton University
Targeting
Cell Death/Apoptosis
Douglas R. Green, Ph.D.
Doherty Chair of Immunology, Department of Immunology
St.
Jude Children’s Research
Hospital
New
Horizons In Therapeutic Intervention for Hematologic Neoplasias
Kenneth Anderson, M.D.
Program Director, Hematologic Neoplasias
Dana Farber Cancer Institute
Value
Based Pricing for Oncology Drugs, including the Role of Biomarkers In Pricing
–
Will They Help to Set Price Points, Affect Reimbursement?
Vice President
DaVinci Oncology Specialists, a
Unit of The Mattson Jack Group
An
Update on FDA Regulations
Daniel Troy, Esq.
Former Chief
Counsel, FDA
Partner
Sidley Austin LLP
Panel Discussion:
Immunotherapy
of Cancer – What’s Working – What’s Not? Is it Clinical Design?
If we need to go very
personalized, will Big Pharma walk away?
Moderator:
Michael T. Lotze, M.D.
Professor of Surgery & Bioengineering
Assistant Vice Chancellor
University of Pittsburgh SHS
Associate Director, Strategic Partnerships
University of Pittsburgh Cancer Institute
Panelists:
Elizabeth M.
Jaffee, M.D.
The Dana and Albert (Cubby) Broccoli Professor of Oncology
Co-Director, Division of Immunology and Hematologic Malignancies
Co-Director, Gastrointestinal Cancers Program
Sidney
Vincent
T.
Brichard,
M.D.,
Ph.D.
Vice President Cancer Immunotherapeutics
GlaxoSmithKline
Carl H. June, M.D.
Director, Translational Research
Abramson
Cancer Center
Professor of Pathology and Laboratory Medicine
University of
Pennsylvania
Mark
Vincent,
M.D.
Director, Investigational Oncology
Chair, Scientific Advisory Board
YM Biosciences
David Berd,
M.D.
Chief Medical Officer
AVAX Technologies
Panel
Discussion: Dealmaking
in Oncology – What is Big Pharma Looking For?
Moderator:
Roger
Longman
Managing Partner
Windhover Information
Panelists: George Golumbeski,
Ph.D.
Vice President, Business Development & Licensing / Strategy
Novartis
Thomas Hofstaetter,
Ph.D.
Senior Vice President, Corporate Business Development
Wyeth
Mervyn J.
Turner, Ph.D.
Senior Vice President, Worldwide Licensing & External Research
Merck & Co.
Merck Research Laboratories
Warwick
S.
Bedwell
Vice President and Global Head, Business Development - Pharma Partnering
Roche
Dr. Daniel Teper
Managing Director, North America
Bionest Partners
The Future of Cytotoxic Chemotherapy - Is the field dead or alive?
Robert Kramer, Ph.D.
Vice President Biology Drug Discovery
Bristol-Myers Squibb
An
Update on New Therapeutics for Prostate Cancer
Chief Clinical Research Officer
Chief, Division of Solid Tumor Oncology
Director, Lank Center for Genitourinary Oncology
Professor of Medicine
Harvard Medical School